Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia
Authors:
- 25 April 2007
- journal article
- Published by Wiley in Transfusion
- Vol. 47 (5) , 901-910
Abstract
BACKGROUND: Fetomaternal alloimmune thrombocytopenia (FMAIT) is the commonest cause of severe thrombocytopenia in term neonates but its management remains controversial.STUDY DESIGN AND METHODS: A 7‐year prospective observational study of 200 cases of FMAIT evaluated the relationship between human platelet antigen (HPA) antibody specificity, clinical presentation, morbidity, mortality, and therapeutic interventions in the antenatal and postnatal period, with long‐term follow‐up of neonates with intracranial hemorrhage (ICH).RESULTS: In 1148 referrals for FMAIT, HPA antibodies were confirmed in 200 (17%). The commonest specificities were anti‐HPA‐1a, 150 (75%); anti‐HPA‐5b, 31 (15.5%); and anti‐HPA‐15b, 8 (4%). Of 123 (62%) cases (two sets of twins) with no previous history of FMAIT, intrauterine deaths occurred in 5: anti‐HPA‐1a alone, 3; in combination with anti‐HPA‐5b, 1; and anti‐HPA‐15b, 1. Of the 120 live neonates, 103 had severe thrombocytopenia and 17 (14%) developed ICH (anti‐HPA‐1a, 13; anti‐HPA‐5b, 3; anti‐HPA‐15b, 1). Postnatal care varied widely with 37 percent of neonates receiving random rather than HPA‐1a and ‐5b–negative platelets. Of the remaining 77 cases with a history of FMAIT, 40 received intrauterine transfusions. Six (15%) of these fetuses died in utero and an additional 2 developed ICH postnatally. Of the 19 children with ICH, 1 (anti‐HPA‐15b) died on Day +1, and neurologic sequelae persist in 13 (mean follow‐up, 2.5 years).CONCLUSION: HPA‐1a antibodies are most commonly implicated in severe thrombocytopenia but HPA‐5b and HPA‐15b antibodies can also result in poor outcome. Postnatal transfusion management is extremely variable, and fetal transfusions are associated with significant morbidity and mortality.Keywords
This publication has 39 references indexed in Scilit:
- Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activityBlood, 2006
- Frequencies of maternal platelet alloantibodies and autoantibodies in suspected fetal/neonatal alloimmune thrombocytopenia, with emphasis on human platelet antigen‐15 alloimmunizationVox Sanguinis, 2005
- Microarray‐based genotyping for blood groups: comparison of gene array and 5′‐nuclease assay techniques with human platelet antigen as a modelTransfusion, 2005
- Functional heterogeneity of alloantibodies against the human platelet antigen (HPA)-1aThrombosis and Haemostasis, 2005
- Survey of the use and clinical effectiveness of HPA-1a/5b-negative platelet concentrates in proven or suspected platelet alloimmunizationTransfusion Medicine, 2004
- Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cellsClinical and Experimental Immunology, 2004
- The effect of recombinant IgG antibodies against the leucine-33 form of the platelet β3 integrin (HPA-1a) on platelet functionThrombosis and Haemostasis, 2004
- Neonatal alloimmune thrombocytopenia due to anti‐HPA 1a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newbornBJOG: An International Journal of Obstetrics & Gynaecology, 2000
- A rapid one‐stage whole‐blood HPA‐1a phenotyping assay using a recombinant monoclonal IgG1 anti‐HPA‐1aBritish Journal of Haematology, 2000
- Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activitiesEuropean Journal of Immunology, 1999